Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
Agomelatine (1) ·
Amoxapine (1) ·
Asenapine (1) ·
Chlorpromazine (1) ·
Clomipramine (1) ·
Clozapine (1) ·
Desipramine (1) ·
Droperidol (1) ·
Duloxetine (1) ·
Fluphenazine (1) ·
Iloperidone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Molindone (1) ·
Nefazodone (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Phenelzine (1) ·
Pimozide (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trifluoperazine (1) ·
Trimipramine (1) ·
Ziprasidone (1)
brand:
None (1) ·
Anafranil (1) ·
Aurorix (1) ·
Clozaril (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fanapt (1) ·
Fetzima (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Ludiomil (1) ·
Marplan (1) ·
Mellaril (1) ·
Moban (1) ·
Nardil (1) ·
Navane (1) ·
Norpramin (1) ·
Orap (1) ·
Parnate (1) ·
Prolixin (1) ·
Rexulti (1) ·
Saphris (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Stelazine (1) ·
Surmontil (1) ·
Thorazine (1) ·
Tofranil (1) ·
Trilafon (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Phenothiazine D2 antagonist (4) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Thioxanthene D2 antagonist (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (34) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
legal:
Showing below up to 36 results in range #1 to #36.